Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials

Conclusion: DPL improved upper and lower airway outcomes and reduced type 2 biomarkers in CRSwNP pts with NSAID-ERD in the pooled SINUS-24/52 population and was well tolerated.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Laidlaw, T. M., Mullol, J., Canonica, G. W., Bachert, C., Han, J. K., Zhang, M., Lu, X., Patel, N., Graham, N. M., Staudinger, H., Mannent, L. P., Amin, N. Tags: Allergy and immunology Source Type: research